Table 1.
Study | Random sequence generation | Allocation concealment | Blinding: Participants | Blinding: Personnel | Blinding: Outcomes | Incomplete outcome assessment | Selective reporting | Other |
---|---|---|---|---|---|---|---|---|
Randomized controlled trials | ||||||||
Bladh et al. 26 | Unclear | Low | High | High | Mortality: Unclear | Mortality: High | High | |
LOA: Unclear | LOA: Low | |||||||
Gillespie et al. 25 | High | Unclear | Unclear | Unclear | Mortality: Unclear | Mortality: Low | Low | Low |
Re-admissions: Low | Re-admissions: Low | |||||||
ED revisits: Low | ED revisits: Low | |||||||
Lisby et al. 23 | Unclear | Unclear | Unclear | High | Mortality: Unclear | Mortality: Low | Low | |
LOA: Unclear | LOA: Low | |||||||
Re-admissions: Unclear | Re-admissions: Low | |||||||
ED revisits: Unclear | ED revisits: Low | |||||||
Lisby et al. 22 | Unclear | Unclear | Low | High | Mortality: Unclear | Mortality: Low | Low | High |
LOA: High | LOA: Low | |||||||
Re-admissions: Unclear | Re-admissions: Low | |||||||
ED revisits: Unclear | ED revisits: Low | |||||||
Scullin et al. 20 | High | Unclear | High | High | Mortality: NA | Mortality: Low | Low | NA |
LOA: High | LOA: Unclear | |||||||
Re-admissions: High | Re-admissions: Unclear | |||||||
Controlled clinical trials | ||||||||
Makowsky et al. 24 | High | Unclear | Low | High | LOA: High | LOA: Low | Low | High |
Re-admissions: Unclear | Re-admissions: Low | |||||||
ED revisits: Unclear | ED revisits: Low | |||||||
Spinewine et al. 21 | High | Unclear | Low | High | Mortality: Low | Mortality: High | Unclear | NA |
Re-admissions: High | Re-admissions: High | |||||||
ED re-visits: High | ED re-visits: High |
CCT, controlled clinical trial;
HRQL, health-related quality of life;
LOA, length of admission;
NA, not applicable;
RCT, randomized controlled trial.